EUDA Health Holdings (NASDAQ:EUDA) has unveiled a nationwide stem cell extraction, cryostorage, and clinical delivery platform in China, marking a massive expansion of its footprint in the regional longevity and regenerative medicine sector.
Announced on Dec. 30, the platform is built through strategic partnerships with Shenzhen Inno Immune Co. and Wuhan Kaien Hospital.
The infrastructure is designed to provide a "closed-loop" ecosystem that connects decentralized extraction clinics across China to centralized high-tech processing and storage hubs.
The initial infrastructure includes a primary cell processing hub in Shenzhen with an initial capacity of approximately 50,000 patient units.
This will be followed by a significantly larger facility at Wuhan Kaien Hospital, which is planned to support up to 200,000 patient units.
The Wuhan site will serve as the flagship for EUDA's Central China operations, integrating both inpatient and outpatient services for longevity and chronic disease management.
To ensure the integrity of the samples during transit, EUDA has integrated professional cold-chain logistics to move cellular materials between the network of partner extraction clinics and the central hubs.
The platform also incorporates advanced technologies from EUDA’s partners in Japan and Singapore, including induced pluripotent stem cell (iPSC) platforms intended for anti-aging and immune health applications.
The launch follows a series of aggressive moves by the Singapore-based healthcare provider to dominate the "longevity" market in Asia.
Earlier this week, the company announced the January 2026 launch of its upgraded EUDA Helixé 2.0 supplement and the integration of a QB utility token to power its digital health rewards system.
With over 30% of the regional population aging rapidly, EUDA’s new platform targets a total addressable market of over 1.8 billion people across Singapore, Malaysia, and China who are increasingly seeking proactive, science-backed wellness solutions.